SEC FORM
3
SEC Form 3
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0104 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person*
| C/O ORCHARD THERAPEUTICS PLC |
| 108 CANNON STREET |
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year)
02/03/2020
|
3. Issuer Name and Ticker or Trading Symbol
Orchard Therapeutics plc
[ ORTX ]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
| X |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
|---|
| 1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Explanation of Responses: |
| Remarks: |
|
| No securities are beneficially owned. |
|
/s/ Steven Altschuler |
02/03/2020 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
5
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
LIMITED POWER OF ATTORNEY
The undersigned hereby constitutes and appoints each of John Ilett, Mark
Rothera, and Frank
Thomas, signing singly, and with full power of substitution, the undersigned's
true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as
officer and/or director of Orchard Therapeutics plc (the "Company"), from time
to time the
following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID,
including any
attached documents (such as Update Passphrase Authentication), to effect the
assignment of
codes to the undersigned to be used in the transmission of information to the
SEC using the
EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of
Securities, including
any attached documents; (iii) Form 4, Statement of Changes in Beneficial
Ownership of
Securities, including any attached documents; (iv) Form 5, Annual Statement of
Beneficial
Ownership of Securities in accordance with Section 16(a) of the Securities
Exchange Act of
1934, as amended, and the rules thereunder, including any attached documents;
(v) Schedule
13D and (vi) amendments of each thereof, in accordance with the Securities
Exchange Act of
1934, as amended, and the rules thereunder, including any attached documents;
(2) do and perform any and all acts for and on behalf of the undersigned which
may
be necessary or desirable to complete and execute any such Form 3, 4 or 5,
Schedule 13D or any
amendment(s) thereto, and timely file such form(s) with the SEC and any
securities exchange,
national association or similar authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing
which, in the opinion of such attorney-in-fact, may be of benefit to, in the
best interest of, or
legally required by, the undersigned, it being understood that the documents
executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney
shall be in such
form and shall contain such terms and conditions as such attorney-in-fact may
approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact, acting singly, full
power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or
proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all
intents and purposes as the undersigned might or could do if personally present,
with full power
of substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to
be done by virtue of
this power of attorney and the rights and powers herein granted. The undersigned
acknowledges
that the foregoing attorneys-in-fact, in serving in such capacity at the request
of the undersigned,
are not assuming, nor is the Company assuming, any of the undersigned's
responsibilities to
comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of
1934, as
amended. The undersigned hereby agrees to indemnify the attorneys-in-fact and
the Company
from and against any demand, damage, loss, cost or expense arising from any
false or misleading
information provided by the undersigned to the attorneys-in-fact.
This Power of Attorney shall be governed by, and construed in accordance with,
the laws
of the state of Delaware. This Power of Attorney shall remain in full force and
effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of
and transactions in securities issued by the Company, unless earlier revoked by
the undersigned
in a signed writing delivered to the foregoing attorneys-in-fact. This Power of
Attorney
supersedes any prior power of attorney in connection with the undersigned's
capacity as an
officer and/or director of the Company. This Power of Attorney shall expire as
to any individual
attorney-in-fact if such attorney-in-fact ceases to be an officer of, or legal
counsel to, the
Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of January 31, 2020.
/s/ Steven M Altschuler, MD
----------------------
Steven M Altschuler, MD
